Key Highlights

● Wang Erqi's beneficial ownership fell from 6.77% to 3.35% after Jin Medical issued 79,762,048 new Class A shares.

● The issuance was tied to an Acquisition and financial advisory compensation, with no funds contributed by Wang.

● Wang's voting power dropped only slightly, from 98.12% to 96.15%, reflecting his concentrated voting rights.

● His stake falling below 5% means he may no longer be required to file ongoing Schedule 13D amendments.

Jin Medical International (NASDAQ:ZJYL) insider Wang Erqi filed a Schedule 13D/A on September 25, 2026 disclosing that his beneficial ownership was diluted from 6.77% to 3.35% after the company issued 79,762,048 new Class A ordinary shares on September 24, 2026, a transaction he says he did not fund and that pushes his stake below the threshold requiring continued 13D reporting.

What Triggered the Filing

The amendment, filed jointly by Wang and co-filer Jolly Harmony Enterprises Limited, states that Jin Medical completed the distribution of the new Class A shares to third parties on September 24, 2026. Per the filing, the issuance was tied to "an acquisition transaction and related financial advisory compensation," though the amendment does not name the acquisition or the advisory arrangement in further detail. The filing is explicit that Wang's group "did not provide any funds or other consideration" in connection with that issuance; his percentage ownership fell purely because the total share count expanded.

A dilution of this kind is a mechanical consequence of simple arithmetic rather than a sale of stock: Wang's own number of shares did not shrink, but the denominator used to calculate his percentage of the company grew by 79,762,048 shares in a single day, which is why the drop in his reported ownership percentage looks large even though he made no trade.

The Numbers Behind the Dilution

Before the issuance, Wang's group reported 6.77% beneficial ownership; afterward, that fell to 3.35%. Voting power similarly declined, from 98.12% to 96.15%, a smaller drop reflecting the concentrated voting rights attached to Wang's holdings. His beneficial stake consists of roughly 5.3 million shares in total: about 4.77 million Class B shares held through Jolly Harmony, which convert into Class A shares on a one-for-one basis, plus 537,250 Class A shares held through a separate entity, Er Pu International Limited.

Why This Is an Exit Filing

Because Wang's ownership fell below the 5% level that requires ongoing Schedule 13D reporting, this amendment functions as an exit filing: absent a future increase in his stake, he will not be required to keep filing 13D amendments on Jin Medical going forward. The filing frames the dilution as involuntary from Wang's perspective, since he neither bought into the new issuance nor otherwise added to his position; the reduction in his percentage stake results mechanically from the larger number of shares now outstanding.

Company Background From the Filing

Jin Medical International Ltd. is classified in SEC records under orthopedic, prosthetic and surgical appliance and Supply manufacturing, and its Class A ordinary shares trade on Nasdaq under the ticker ZJYL. The 13D/A does not provide additional description of the company's product lines or the specifics of the acquisition that prompted the new share issuance beyond the brief characterization already noted; investors seeking more detail on the underlying deal would need to consult Jin Medical's own disclosures about the acquisition and the related financial advisory compensation.

Open Questions the Filing Leaves Behind

Because Wang's stake has dropped below the 5% reporting threshold, watch for whether he continues any SEC ownership reporting at all going forward, or whether this filing is his last on the Schedule 13D track for Jin Medical. Investors should also watch Jin Medical's own filings for details of the acquisition that the new shares were apparently issued to help fund or compensate, since the 13D/A itself does not name the counterparty or the terms of that underlying transaction. Any subsequent filing describing the recipients of the 79,762,048 shares, or the specific advisory fees involved, would Fill in detail this amendment leaves out.